Affiliation:
1. Department of Neurology and Center for Genomic Medicine, Massachusetts General Hospital , Boston, Massachusetts , USA
2. Center for Childhood Cancer, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University College of Medicine , Columbus, Ohio , USA
3. Department of Biochemistry and Goodman Cancer Research Institute, McGill University , Montreal, Quebec , Canada
4. Cancer Center, Massachusetts General Hospital , Boston, Massachusetts , USA
Abstract
Abstract
Background
NF2-associated meningiomas are progressive, highly morbid, and nonresponsive to chemotherapies, highlighting the need for improved treatments. We have established aberrant activation of the mechanistic target of rapamycin (mTOR) signaling in NF2-deficient tumors, leading to clinical trials with first- and second-generation mTOR inhibitors. However, results have been mixed, showing stabilized tumor growth without shrinkage offset by adverse side effects. To address these limitations, here we explored the potential of third-generation, bi-steric mTOR complex 1 (mTORC1) inhibitors using the preclinical tool compound RMC-6272.
Methods
Employing human NF2-deficient meningioma lines, we compared mTOR inhibitors rapamycin (first-generation), INK128 (second-generation), and RMC-6272 (third-generation) using in vitro dose–response testing, cell-cycle analysis, and immunoblotting. Furthermore, the efficacy of RMC-6272 was assessed in NF2-null 3D-spheroid meningioma models, and its in vivo potential was evaluated in 2 orthotopic meningioma mouse models.
Results
Treatment of meningioma cells revealed that, unlike rapamycin, RMC-6272 demonstrated superior growth inhibitory effects, cell-cycle arrest, and complete inhibition of phosphorylated 4E-BP1 (mTORC1 readout). Moreover, RMC-6272 had a longer retention time than INK128 and inhibited the expression of several eIF4E-sensitive targets on the protein level. RMC-6272 treatment of NF2 spheroids showed significant shrinkage in size as well as reduced proliferation. Furthermore, in vivo studies in mice revealed effective blockage of meningioma growth by RMC-6272, compared with vehicle controls.
Conclusions
Our study in preclinical models of NF2 supports possible future clinical evaluation of third-generation, investigational mTORC1 inhibitors, such as RMC-5552, as a potential treatment strategy for NF2.
Funder
National Institutes of Health
U.S. Department of Defense
Publisher
Oxford University Press (OUP)
Reference50 articles.
1. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene;Baser;Hum Mutat.,2006
2. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2;Jordan;Neurooncol Adv,2023
3. An update on the CNS manifestations of neurofibromatosis type 2;Coy;Acta Neuropathol.,2020
4. Genomic landscape of meningiomas;Wang,2023
5. Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues;Vagnoni;Neurosurg Rev.,2022